A new prognostic staging system for hepatocellular carcinoma: Value of the biomarker combined Japan integrated staging score

Intervirology

Volumn 51, Issue SUPPL. 1, 2008, Pages 86-94

  Kitai, Satoshi ^a   Kudo, Masatoshi ^a   Minami, Yasunori ^a   Ueshima, Kazuomi ^a   Chung, Hobyung ^a   Hagiwara, Satoru ^a   Inoue, Tatsuo ^a   Ishikawa, Emi ^a   Takahashi, Shunsuke ^a   Asakuma, Yutaka ^a   Haji, Seiji ^a   Osaki, Yukio ^b   Oka, Hiroko ^c   Seki, Toshihito ^d   Kasugai, Hiroshi ^e   Sasaki, Yo ^e   Matsunaga, Takashi ^e  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Fetoprotein; AFP L3; Biomarkers; Des carboxy prothrombin; Japan Integrated Staging score; Lens culinaris

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PLANT LECTIN;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FEMALE; HUMAN; JAPAN INTEGRATED STAGING SCORE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JAPAN; LENS PLANT; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

LENS CULINARIS;

EID: 44949240446     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122599     Document Type: Conference Paper

References (36)

1. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-215.
2. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
3. Pugh RNH, Murray-Lyon IM, Dawson JL: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-669.
4. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 4 (in Japanese). Tokyo, Kanehara, 2000.
5. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 4. Tokyo, Kanehara, 2003.
6. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
7. Taketa K, Sekiya C, Namiki N, et al: Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-518.
8. Liebman HA, Furie BC, Tong MJ, et al: Desgamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
9. Fujiyama S, Tanaka M, Maeda S, et al: Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002;62:S57-S63.
10. Kudo M, Okanoue T; Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72:S2-S15.
11. Torzilli G, Minagawa M; Takayama T, Inoue K, Hui AM, Kubota K, et al: Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889-893.
12. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
13. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006;4:1528-1536.
14. Kaplan EL, Meier P: Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
15. Petro R, Pike MC: Conservation of the approximation for (0-E2)/E in the log rank test for survival data on tumor incidence data. Biometrics 1973;29:579-584.
16. Akaike H: A new look at statistical model identification. IEEE Trans Autom Control 1974;19:716-722.
17. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, et al: Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572-1577.
18. Lui WY, Chiu ST, Chiu JH, Loong CC, Chau GY, King KL, Hsia CY, et al: Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma. J Formos Med Assoc 1999;4:248-253.
19. Calvet X, Bruix J, Bru C, Gines P, Vilana R, Sole M, Ayuso MC, et al: Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. J Hepatol 1990;10:311-317.
20. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, et al: Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104-1110.
21. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-755.
22. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: BLCL staging classification. Semin Liver Dis 1999;19:329-337.
23. Toyoda H, Kumada T, Kiriyama S, et al: Comparison of usefulness of three staging systems for hepatocellular carcinoma (CLIP, BLCL, JIS) in Japan. Am J Gastroenterol 2005;100:1764-1771.
24. Nakashima O, Sugihara S, Kage M, et al: Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101-105.
25. Oka H, Tamori A, Kuroki T, et al: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.
26. Ikeda K, Saitoh S, Koida I, et al: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
27. Yamashita F, Tanaka M, Satomura S, Tanikawa K: Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001.
28. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H: Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 1998;83:2076-2082.
29. Kobayashi M, Kuroiwa T, Suda T, Tamura Y, Kawai H, Igarashi M, Fukuhara Y, Aoyagi Y: Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 2007;37:914-922.
30. Tada T, Kumada T, Toyoda H, et al: Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathological features of hepatocellular carcinoma. Liver Int 2005;25:848-853.
31. Kasahara A, Hayashi N, Fusamoto H, et al: Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-2176.
32. Hamamura K, Shiratori Y, Shiina S, et al: Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88:1557-1564.
33. Suehiro T, Sugimachi K, Matsumata T, et al: Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alphafetoprotein. Cancer 1994;73:2464-2471.
34. Koike Y, Shiratori Y, Sato S, et al: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
35. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4:111-117.
36. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamasaki N, Yoshida H, Akamatsu M, Kawabe T, Omata M: Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518-1527.